X

Hematology Advisor

Hematology Advisor
CD38 CAR-T Cell Therapy May Be Promising for Patients With Multiple Myeloma

A novel CAR T-cell therapy targeting CD38 may be an effective option for multiple myeloma, according to research published in Frontiers in Oncology.

Hematology Advisor
11/04/2021
Indatuximab Ravtansine Has Encouraging Activity in Relapsed/Refractory Multiple Myeloma

Indatuximab ravtansine with lenalidomide or pomalidomide shows encouraging clinical activity for R/R MM, according to data from a phase 1/2a study published in the Lancet Haematology.

Hematology Advisor
11/23/2021
CEBPA-bZip Mutations Associated With Favorable Prognosis in Acute Myeloid Leukemia

CEBPA-bZip mutations, whether monoallelic or biallelic, are associated with favorable outcomes from AML, similar to those with CEBPA-dm, according to research published in Blood.

Hematology Advisor
11/19/2021
MiR-22 Mimics With Lenalidomide Help Inhibit MYC Expression, Improve Drug Resistance in Multiple Myeloma

Lenalidomide combined with miR-22 mimics may sensitize multiple myeloma cells to help overcome drug resistance, according to research published in Cancers.  

Hematology Advisor
11/17/2021
Zanubrutinib Shows Promising Response Rate in Relapsed, Refractory Marginal Zone Lymphoma

Researchers sought to determine whether zanubrutinib would have a positive response in patients with relapsed/refractory marginal zone lymphoma.

Hematology Advisor
11/15/2021
IR-neoAg Load Predicts Prognosis in Both Newly Diagnosed and Relapsed Multiple Myeloma

Among patients with multiple myeloma, IR-neoAg load may predict prognosis, according to research published in Oncogene.

Hematology Advisor
11/16/2021
ASA: Dexamethasone Use During Cancer Surgery May Reduce Mortality

Administration of dexamethasone during cancer surgery for prevention of nausea and vomiting after surgery is associated with reduced 90-day mortality, according to a new study. 

Hematology Advisor
11/11/2021
MRD Assessment Can Guide Treatment Discontinuation in CLL/SLL

MRD assessment can be used to guide treatment discontinuation in patients with CLL/SLL, according to phase 2 results published in the Journal of Clinical Oncology.

Hematology Advisor
11/11/2021
CD38 CAR-T Cell Therapy May Be Promising for Patients With Multiple Myeloma

A novel CAR T-cell therapy targeting CD38 may be an effective option for multiple myeloma, according to research published in Frontiers in Oncology.

Hematology Advisor
11/04/2021
Factors Associated With Low Palliative Care Consultation in Hospitalized Patients at the End of Life

Among patients who were hospitalized at the end of life, early palliative care consultation was significantly lower for those with hematological malignancies than for those with other malignancies.

Hematology Advisor
11/02/2021
Subscribe to Hematology Advisor

source list reference

rgb(171, 222, 222)
#7d60d9
rgb(219, 18, 118)
#2694a4
#32a887
200, 66, 245
#85eb24
rgb(195, 2, 230)
rgb (247, 7, 79)
#352625
#4d4537
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
#d2093c
#8e3f1c
rgb(242, 0, 137)
rgb (247, 7, 79)
#76b6c3
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
#bfcfc8
rgb (252, 186, 3)
#c61417
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
#67e25b
#efef71
#03cffc
rgb(224, 4, 129)
#42fc9a
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
#cc529a
#c59445
#c8cc0c
#bf6be3
rgb (245, 152, 2)
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
rgb(169, 196, 201)
#a153ac
rgb(5, 235, 235)
#e7f6e3
#6fc969
#9a8c2c
#a9c507
rgb(235, 190, 9)
#2b9ab3
#e61923
rgb(209, 227, 11)
#990677
#4a7bab
200, 66, 245
rgb (191, 171, 145)
#89f67c
#49a21d
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
#2c990a
rbg(16, 162, 230)
#d7da81
#f5ce42
rgb(217, 7, 192)
#575662
rgb(224, 224, 4)
#a60538
rgb(2, 230, 230)
rgb(235, 64, 52)
#49cde9
#c20fce
rgb(80,199,199)
#d95d39
#eb5834